Debate Continues on Esketamine Efficacy and Safety for Depression Treatment

Debate Continues on Esketamine Efficacy and Safety for Depression Treatment

PHILADELPHIA—Is esketamine a revolutionary treatment for depression or just another moderately effective adjunctive medication with some potentially serious risks? The VA’s Medical Advisory Panel leaned toward the latter position when it decided in June to approve the use of esketamine on a nonformulary basis for individuals who have previously failed at least two trials of other antidepressants.

Link Between Pain, Brain Disruption in Gulf War Veterans

MADISON, WI — Chronic musculoskeletal pain (CMP) affects about one-fourth of the 700,000 veterans deployed during the Persian Gulf War in 1990-1991. A study in the journal Pain pointed out that the cause of their pain is unknown, and no efficacious treatments...

VA Patients Lack Testing to Optimize CLL Treatment

SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1

U.S. Medicine Archives

U.S. Medicine Supplements

CE Credits